PER-078-02已完成未知
STUDY ON THE SAFETY AND TOLERANCE OF MULTIPLE DOSE OF DESLORATADINE IN PEDIATRIC SUBJECTS ATOPICOS AND PEDIATRIC SUBJECTS WITH CIU, FROM> 2 TO <12 YEARS OF AGE, WHICH ARE SLOW METABOLIZERS OF DYSORATADINE
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •have been previously identified through the previous study P03031 to be atopic or with chronic idiopathic urticaria and be a poor metabolizer of desloratadine.
- •have clinical laboratory tests within normal limits.
- •be in good health, free of any clinically significant disease that could interfere with the study.
- •normal 12-lead ECG
排除标准
- •have a history of any clinically significant local or systemic infectious disease within 4 weeks prior to treatment.
- •have taken any medication that is restricted by the protocol or failed to satisfy washout requirements.
- •are allergic to desloratadine.
- •have used a loratadine- or desloratadine-containing product within the past 30 days.
- •are female and menstruating.
研究者
相似试验
进行中（未招募）
1 期
MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSACystic fibrosisEUCTR2006-006980-22-SKTransave, Inc.60
进行中（未招募）
1 期
MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSACystic fibrosisEUCTR2006-006980-22-PLTransave, Inc.60
进行中（未招募）
不适用
MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSAMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic fibrosisEUCTR2006-006980-22-BETransave, Inc.60
进行中（未招募）
不适用
MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSACystic fibrosisMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisEUCTR2006-006980-22-HUTransave, Inc.60
进行中（未招募）
不适用
Clinical trials assessing efficacy, safety and tolerability of different doses of oral cebranopadol in patients with moderate to severe chronic pain due to diabetic peripheral neuropathyEUCTR2013-000473-68-NLGrünenthal GmbH350